Your session is about to expire
← Back to Search
Alpha-glucosidase Inhibitor
2 for Chronic Hepatitis C
Phase 2
Waitlist Available
Research Sponsored by BioWest Therapeutics Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights
Study Summary
The objective of this study is to undertake an initial evaluation of the safety, tolerability, antiviral effect, and pharmacokinetics of celgosivir in combination with peginterferon alfa-2b and ribavirin in patients with chronic HCV infection.
Eligible Conditions
- Chronic Hepatitis C
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
HCV viral load
Pharmacokinetics of celgosivir/castanospermine
Safety analysis
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: 2Experimental Treatment1 Intervention
Group II: 1Experimental Treatment1 Intervention
Group III: 3Active Control1 Intervention
Find a Location
Who is running the clinical trial?
BioWest Therapeutics IncLead Sponsor
6 Previous Clinical Trials
1,893 Total Patients Enrolled
Jim PankovichStudy DirectorBioWest Therapeutics Inc
6 Previous Clinical Trials
1,893 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger